Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target
Score
Vertex Pharmaceuticals Incorporated price target
| VRTX | |
|---|---|
| Low | $350.00 |
| Average | $580.20 |
| High | $665.00 |
| Upside vs current price | +6.1% |
The average target of $580.20 is +6.1% versus the current VRTX price of $547.03.
Vertex Pharmaceuticals Incorporated analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 6 |
| Buy | 20 |
| Hold | 4 |
| Sell | 1 |
| Strong sell | 1 |
| Consensus | Buy |
32 analysts cover VRTX.
Vertex Pharmaceuticals Incorporated EPS and revenue estimates
The estimate table for the Vertex Pharmaceuticals Incorporated keeps 2026 EPS $18.25, 2027 EPS $20.19, and years with fewer than three analysts are not filled in.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $18.25 | $13.25B |
| 2027 | $20.19 | $14.68B |
Is Vertex Pharmaceuticals Incorporated a buy or sell?
Of the 32 analysts covering Vertex Pharmaceuticals Incorporated, 26 rate it a buy (6 strong buy and 20 buy), 4 rate it a hold, and 2 rate it a sell (1 sell and 1 strong sell).
The VRTX consensus label is Buy, beside 26 buy-side ratings and 2 sell-side ratings.
The average target of $580.20 implies +6.1% versus the current price of $547.03.
the Vertex Pharmaceuticals Incorporated closes with 26 buy-side ratings and 2 on the sell side. The headcount is Buy.
Reading the Vertex Pharmaceuticals Incorporated forecast
Analysts are far apart on VRTX. The published low is $350.00, the average is $580.20, and the high is $665.00.
From today's $547.03 print, the VRTX average target is +6.1% away.
Most of the VRTX coverage agrees: 26 of 32 analysts are on the buy side, 4 are at hold, and 2 are on the sell side, and the published consensus is Buy.
The VRTX average target is little changed, $615.00 over the last month and $617.58 over the last quarter.
Coverage of VRTX is broad at 32 analysts, and the average is a crowd rather than a single desk.
Vertex Pharmaceuticals Incorporated forecast questions
What is the VRTX price target?
The published range for VRTX is $350.00 to $665.00, with an average of $580.20. That average is +6.1% versus the current price of $547.03.
Is Vertex Pharmaceuticals Incorporated a buy or sell?
Of the 32 analysts covering Vertex Pharmaceuticals Incorporated, 26 rate it a buy, 4 rate it a hold, and 2 rate it a sell. The consensus is Buy, which for VRTX is 26 on the buy side, 4 at hold, and 2 on the sell side.
What is the EPS estimate for Vertex Pharmaceuticals Incorporated?
Analyst EPS estimates for Vertex Pharmaceuticals Incorporated: 2026 $18.25, 2027 $20.19.
What is the revenue estimate for Vertex Pharmaceuticals Incorporated?
Analyst revenue estimates for Vertex Pharmaceuticals Incorporated: 2026 $13.25B, 2027 $14.68B.
How many analysts cover VRTX?
32 analysts cover VRTX. Their consensus on VRTX is Buy, across those 32.